For more information on cookies, change your preferences or delete the installation of cookies, click on the " Cookie Policy " link available at the bottom of each page of the website www.diasorin.com by accessing the " Privacy Policy " section. DiaSorin LIAISON ® MeMed BV® The new innovative solution for accurate and rapid differentiation between bacterial and viral infections The growing development of antimicrobiotic resistance represents one of the major threats to public health worldwide. The excessive use of antibiotics in particular is often the consequence of a limited ability to differentiate quickly and accurately the etiology of the infection. A rapid and accurate diagnosis is therefore essential to support clinical decisions, optimize the patient's quality of life and limit the health and social consequences of the onset of antibiotic resistance. Il nuovo LIAISON® MeMed BV® è il primo test CLIA completamente automatizzato, ad elevato throughput che consente il differenziamento tra infezioni batteriche e virali. Questa innovativa soluzione diagnostica, ora disponibile sugli analizzatori LIAISON®, si basa sul rilevamento di tre proteine (TRAIL, IP-10 and CRP) che sono coinvolte nella risposta immune dell’ospite ad un’infezione. Attraverso l’elaborazione automatica di un algoritmo, il test fornisce un risultato semi-quantitativo in grado di differenziare la sorgente dell’infezione in modo semplice, rapido ed accurato a partire da un campione di siero umano. The LIAISON ® MeMed BV ® test supports a more effective treatment path for the patient and contributes to the more prudent administration of antibiotic and antiviral drugs. WHO WE ARE CLINICAL AREAS Infectious diseases Hepatitis and Retroviruses TORCH EBV MMRV Borrelia LymeDetect ® Respiratory Infections Sepsis Tuberculosis Other infectious diseases Zika COVID-19 LIAISON ® MeMed BV® Bone and mineral metabolism Endocrinology Hypertension Oncology Gastrointestinal infections Autoimmunity SYSTEMS DEDICATED TO EFFICIENCY NEWS EVENTS CONTACTS Download the APP for the laboratories Diasorin Group Molecular Diasorin Luminex Corporation Legal Privacy Modern Slavery Act Statement DiaSorin SpA - Share Capital € 55.948.257 REA 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155 English Italian INTERNATIONAL USA Disclaimer : the DIASORIN site content linked here is for outside the United States only . Continue to our International Section Disclaimer : the DIASORIN site content linked here is for United States only . Continue to our US Section Pursuant to the Guidelines of the Ministry of Health of 28/03/2013, relating to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, the user is advised that the information contained in this website and to which you are about to access are exclusively aimed at professional operators Pursuant to the Guidelines of the Ministry of Health dated 28/03/2013 related to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, we hereby inform you that the information contained in this website and to which you are going to access is exclusively intended for professional operators